Rasilez® (aliskiren), the first-in-class direct renin inhibitor, has shown clinically meaningful reductions in left ventricular hypertrophy, a proven predictor of heart disease, that are comparable t
read more » Discuss Add this link to...Bury Add to:
| Bookmarks